Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-08-16
2005-08-16
Henley III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06930103
ABSTRACT:
The invention describes and claims the use of vasopeptidase inhibitors of formula (I)for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and/or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.
REFERENCES:
patent: 5430145 (1995-07-01), Flynn et al.
patent: 5484783 (1996-01-01), Flynn et al.
patent: 5624921 (1997-04-01), Flynn et al.
patent: 2003/0040509 (2003-02-01), Moskowitz
patent: 0481522 (1997-12-01), None
patent: WO 01/15674 (2001-03-01), None
patent: WO 02/083671 (2002-10-01), None
Hofmann et al, RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides, Cell., vol. 97, 1999, pp 889-901.
Bralet J et al., Vasopeptidase Inhibitors: an emerging class of cardiovascular drugs, TRENDS in Pharmacological Sciences, 22 (3), Mar. 2001, pp 106-109.
Kilhovd B et al., The ACE Inhibitor ramipril influences the serum levels of advanced glycation endproducts in high risk patients with coronary artery disease: results from a HOPE substudy, The European Society of Cardiology-XXII Congress, Sep. 1-5, 2001, Stockholm, Sweden, abstract 243.
Lewis Edmund J et al., The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy, N. England J. Med., 329, 1993, pp 1456-1462.
Molinaro Giuseppe et al., Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics, Curr. Opin. Pharmacol., 2002, 2, pp 131-141.
Singh R et al., Advanced glycation end-products: a review, Diabetologia, 44, 2001, pp 129-146.
Bleich Markus
Huber Jochen
Linz Wolfgang
Schäfer Stefan
Aventis Pharma Deutschland GmbH
Balaram Gupta
Henley III Raymond J.
Martin Lawrence L.
LandOfFree
Use of vasopeptidase inhibitors in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of vasopeptidase inhibitors in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vasopeptidase inhibitors in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3518753